Ahn-Gook Pharmaceutical Co., Ltd. (KOSDAQ:001540)
South Korea flag South Korea · Delayed Price · Currency is KRW
10,160
+10 (0.10%)
At close: Sep 11, 2026

Ahn-Gook Pharmaceutical Income Statement

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
345,078306,874271,116233,676205,389163,534
Other Revenue
-0-0---0-
345,078306,874271,116233,676205,389163,534
Revenue Growth
18.68%13.19%16.02%13.77%25.59%14.07%
Cost of Revenue
114,847106,572103,21993,10579,10962,516
Gross Profit
230,230200,302167,896140,571126,279101,018
Selling, General & Admin
177,645160,767145,430121,343102,05283,157
Research & Development
26,06826,89713,25912,25512,95717,328
Amortization of Goodwill & Intangibles
325.31236.38262.3266.24544.69539.11
Operating Expenses
206,595190,504161,219135,509116,899102,102
Operating Income
23,6369,7986,6785,0619,381-1,084
Interest Expense
-2,610-2,755-3,002-142.75-160.41-116.83
Interest & Investment Income
472.12379.07463.68388.54407.43335.82
Earnings From Equity Investments
-1,547-579.821,352-1,641-1,6452,613
Currency Exchange Gain (Loss)
315.9872.1168.82-79.74-82.27133.07
Other Non Operating Income (Expenses)
1,626-231.11,453-258.15336.26-246.68
EBT Excluding Unusual Items
21,8936,6847,0133,3288,2371,634
Gain (Loss) on Sale of Investments
4,509989.18230.47921.68-889.552,033
Gain (Loss) on Sale of Assets
-216.9346.4113,21617.1328.25138.65
Asset Writedown
-2.75-2.75-219.98---
Pretax Income
26,1827,71720,2394,2677,3753,805
Income Tax Expense
4,468397.183,8963,269496.1461.49
Earnings From Continuing Operations
21,7147,31916,343998.286,8793,744
Minority Interest in Earnings
-60.8161.18502.28291.85-3.95195.56
Net Income
21,6537,48116,8451,2906,8753,939
Net Income to Common
21,6537,48116,8451,2906,8753,939
Net Income Growth
254.78%-55.59%1205.72%-81.24%74.54%-
Shares Outstanding (Basic)
111111111111
Shares Outstanding (Diluted)
111111111111
Shares Change
-0.06%-0.01%0.01%-0.12%-0.65%-9.44%
EPS (Basic)
1905.21658.201482.00113.51604.21343.93
EPS (Diluted)
1905.21658.201482.00113.51604.00343.93
EPS Growth
255.00%-55.59%1205.57%-81.21%75.62%-

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Jun '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
29,10037,218-70,972-6,802-1,143-2,563
Free Cash Flow Per Share
2560.443274.68-6243.89-598.47-100.42-223.77
Gross Margin
66.72%65.27%61.93%60.16%61.48%61.77%
Operating Margin
6.85%3.19%2.46%2.17%4.57%-0.66%
Profit Margin
6.28%2.44%6.21%0.55%3.35%2.41%
Free Cash Flow Margin
8.43%12.13%-26.18%-2.91%-0.56%-1.57%
EBITDA
32,98218,57614,37610,08414,3113,423
EBITDA Margin
9.56%6.05%5.30%4.32%6.97%2.09%
D&A For EBITDA
9,3468,7787,6985,0234,9304,507
EBIT
23,6369,7986,6785,0619,381-1,084
EBIT Margin
6.85%3.19%2.46%2.17%4.57%-0.66%
Effective Tax Rate
17.07%5.15%19.25%76.61%6.73%1.62%
Advertising Expenses
-7,33811,3375,5435,7765,482